MDXG Q3 2024 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$84M+2.9% YoY

Gross Profit

$69M81.8% margin

Operating Income

$11M13.3% margin

Net Income

$8M9.6% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

-3.6%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$14M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$244M

Total Liabilities

$63M

Stockholders' Equity

$181M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$82M	+2.9%
Gross Profit	$69M	$67M	+2.7%
Operating Income	$11M	$11M	+0.3%
Net Income	$8M	$9M	-5.1%

Revenue Segments

Surgical

$29M100%